RU2019114205A - Способы лечения глазного заболевания с применением ингибиторов csf-1r - Google Patents
Способы лечения глазного заболевания с применением ингибиторов csf-1r Download PDFInfo
- Publication number
- RU2019114205A RU2019114205A RU2019114205A RU2019114205A RU2019114205A RU 2019114205 A RU2019114205 A RU 2019114205A RU 2019114205 A RU2019114205 A RU 2019114205A RU 2019114205 A RU2019114205 A RU 2019114205A RU 2019114205 A RU2019114205 A RU 2019114205A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- compound
- pharmaceutically acceptable
- acceptable salt
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408345P | 2016-10-14 | 2016-10-14 | |
| US62/408,345 | 2016-10-14 | ||
| PCT/IB2017/056380 WO2018069893A1 (en) | 2016-10-14 | 2017-10-13 | Methods for treating ocular disease using inhibitors of csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019114205A true RU2019114205A (ru) | 2020-11-16 |
Family
ID=60569957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019114205A RU2019114205A (ru) | 2016-10-14 | 2017-10-13 | Способы лечения глазного заболевания с применением ингибиторов csf-1r |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10537563B2 (enExample) |
| EP (1) | EP3525819A1 (enExample) |
| JP (1) | JP2019534269A (enExample) |
| KR (1) | KR20190069459A (enExample) |
| CN (1) | CN109789209A (enExample) |
| AU (1) | AU2017342240A1 (enExample) |
| CA (1) | CA3037116A1 (enExample) |
| IL (1) | IL265596A (enExample) |
| RU (1) | RU2019114205A (enExample) |
| WO (1) | WO2018069893A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019173211A1 (en) * | 2018-03-05 | 2019-09-12 | Massachusetts Eye And Ear Infirmary | Amelioration of autoimmune uveitis through blockade of csf1r |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법 |
| AR062239A1 (es) | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| SI2704713T1 (sl) | 2011-05-05 | 2017-05-31 | Novartis Ag | CSF-1R inhibitorji za zdravljenje možganskih tumorjev |
-
2017
- 2017-10-13 KR KR1020197012853A patent/KR20190069459A/ko not_active Withdrawn
- 2017-10-13 RU RU2019114205A patent/RU2019114205A/ru not_active Application Discontinuation
- 2017-10-13 EP EP17808577.5A patent/EP3525819A1/en not_active Withdrawn
- 2017-10-13 AU AU2017342240A patent/AU2017342240A1/en not_active Abandoned
- 2017-10-13 US US16/341,075 patent/US10537563B2/en not_active Expired - Fee Related
- 2017-10-13 WO PCT/IB2017/056380 patent/WO2018069893A1/en not_active Ceased
- 2017-10-13 JP JP2019519762A patent/JP2019534269A/ja active Pending
- 2017-10-13 CN CN201780060945.4A patent/CN109789209A/zh not_active Withdrawn
- 2017-10-13 CA CA3037116A patent/CA3037116A1/en not_active Abandoned
-
2019
- 2019-03-25 IL IL265596A patent/IL265596A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019534269A (ja) | 2019-11-28 |
| EP3525819A1 (en) | 2019-08-21 |
| CN109789209A (zh) | 2019-05-21 |
| WO2018069893A1 (en) | 2018-04-19 |
| KR20190069459A (ko) | 2019-06-19 |
| US20190231765A1 (en) | 2019-08-01 |
| IL265596A (en) | 2019-05-30 |
| AU2017342240A1 (en) | 2019-04-04 |
| CA3037116A1 (en) | 2018-04-19 |
| US10537563B2 (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112955435B (zh) | Pd-1/pd-l1抑制剂 | |
| JP7349981B2 (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| TWI738632B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| CN108135737B (zh) | 用于治疗翼状胬肉的组合物和方法 | |
| CN104903312B (zh) | Rho激酶抑制剂 | |
| TW201720438A (zh) | 用於治療醫學病症之化合物 | |
| ES2651162T3 (es) | Antagonistas fluorados de integrina | |
| RU2015117536A (ru) | Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний | |
| JP2022501429A5 (enExample) | ||
| TW201718611A (zh) | 用於治療醫學病症之膦酸酯化合物 | |
| TW201718597A (zh) | Ｈｐｋ１抑制劑及其使用方法 | |
| TW201718551A (zh) | 用於治療醫學病症之醯胺化合物 | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| PT2729448E (pt) | Compostos para o tratamento de vih | |
| JP2013540791A5 (enExample) | ||
| WO2021027567A1 (zh) | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 | |
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов | |
| TW200815416A (en) | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| WO2022014707A1 (ja) | 眼疾患の治療薬としてのｔｒｐｖ４阻害薬 | |
| WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists | |
| WO2012105610A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| US10537563B2 (en) | Methods for treating ocular disease using inhibitors of CSF-1R | |
| JP2019534269A5 (enExample) | ||
| JP2016521706A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201014 |